Q (haiku): list the portal studies for pediatric cancers that were published in the last 5 years

▶ list_studies
{
 "search": "pediatric",
 "limit": 100,
 "verbose": true
}

◀ result
{"result":[{"cancer_study_identifier":"all_phase2_target_2018_pub","name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 298 Pediatric Acute Lymphoid Leukemia - Phase II samples. Comprehensive profiling of ALL Phase 2 samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p","type_of_cancer_id":"bll","sample_count":1978,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=all_phase2_target_2018_pub"},{"cancer_study_identifier":"nbl_target_2018_pub","name":"Pediatric Neuroblastoma (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 1089 NBL samples. Comprehensive profiling of 1089 NBL samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p>","type_of_cancer_id":"nbl","sample_count":1089,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=nbl_target_2018_pub"},{"cancer_study_identifier":"aml_target_2018_pub","name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 333 TARGET-AML samples. Comprehensive profiling of TARGET-AML samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnost … (9828 more chars)

═ answer (success)
Based on the search results, here are the **pediatric cancer studies published in the last 5 years (2021–2026)** available in cBioPortal:

## Studies Published 2021–2026

1. **[Pediatric Acute Myeloid Leukemia (St. Jude, Nat Genet 2024)](https://www.cbioportal.org/study/summary?id=aml_stjude_2024)**
   - 887 samples | Published 2024
   - Molecular profiling of pediatric AML cases using RNA-Seq, WES, and WGS

2. **[Pediatric Neuroblastoma (MSK, Nat Genet 2023)](https://www.cbioportal.org/study/summary?id=nbl_msk_2023)**
   - 223 samples | Published 2023
   - Targeted sequencing via MSK-IMPACT

3. **[Pediatric Rhabdomyosarcomas (MSK, JCO Precis Oncol 2023)](https://www.cbioportal.org/study/summary?id=rms_msk_2023)**
   - 24 samples | Published 2023
   - Extremity rhabdomyosarcoma via MSK-IMPACT

4. **[Pediatric solid tumor PDXs (UTHSA, Nat Commun 2023)](https://www.cbioportal.org/study/summary?id=pancan_pdx_uthsa_2023)**
   - 136 samples | Published 2023
   - WGS and WES of patient-derived xenografts and patient tumors

5. **[Pediatric Pan-cancer Tumors (MSK, Nat Commun. 2022)](https://www.cbioportal.org/study/summary?id=mixed_kunga_msk_2022)**
   - 135 samples | Published 2022
   - Mixed pediatric tumors via MSK-IMPACT

6. **[Pediatric European MAPPYACTS Trial (Gustave Roussy, Cancer Discov 2022)](https://www.cbioportal.org/study/summary?id=pancan_mappyacts_2022)**
   - 786 samples | Published 2022
   - Multi-cancer pediatric actionable mutations

7. **[Pediatric Low-Grade Glioma (CTF, Acta Neuropathol 2021)](https://www.cbioportal.org/study/summary?id=lgg_ctf_synodos_2025)**
   - 31 samples | Published 2021
   - WGS of pediatric low-grade gliomas with neurofibromatosis

8. **[Pediatric Tumors (MSK, 2025)](https://www.cbioportal.org/study/summary?id=pancan_ped_mai_msk_2025)**
   - 60 samples | Published 2025
   - Solid and CNS tumors via MSK-IMPACT from the Make An Impact program

**Note:** These represent the most recently published studies. TARGET studies from 2018 (neuroblastoma, AML, Wilms tumor, rhabdoid tumor, ALL) and the 2020 CPTAC pediatric brain cancer study are also available but fall outside the 5-year window.